Given the potential benefit of BAs with synthetic agonists of FXR and FGR5 in dyslipidemia (62), Researchers have found effective agonists for the synthesis of FXR and TGR5 and are currently in phase II or phase III clinical trials (63, 64). Here, NR1H4 is linked to metabolic syndrome.